Tempus AI has expanded its relationship with Personalis, investing $36 million in the oncology biotech and becoming the exclusive commercial partner for its test to detect minimal residual disease, or ...

Personalis (PSNL) and Tempus AI (TEM) announced that the companies have expanded their commercial relationship.The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD ...

We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other ...

Tempus AI TEM is leaning into a dual-engine model: a fast-growing Genomics franchise and a scaling data business powered by an expanding AI toolkit. The third quarter of 2025 marked a turn to non-GAAP ...

Tempus AI, Inc (NASDAQ:TEM) is a healthcare technology company that provides AI-enabled precision medicine solutions. On December 16, the company announced that it has expanded its relationship with ...

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring Tempus AI, Inc.

・Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

Tempus AI has an immunology risk testing product ready for researchers to test out and is working with Cleveland Clinic on better ways to assess how immunotherapy might work on patients. The ...